Autologous hematopoietic stem-cell transplantation in diffuse cutaneous systemic sclerosis: a single-center experience
Abstract
Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by multisystem involvement. Patients can be stratified into an indolent or rapidly progressive disease course. A progressive course warrants early and more aggressive treatment to prevent irreversible organ damage. Therapeutic strategies should be tailored to the presenting symptoms and organ involvement. Autologous hematopoietic stem cell transplantation (AHSCT) has proven to be an effective treatment modality for specific phenotypes of SSc, especially progressive diffuse cutaneous SSc. However, the optimal timing for the transplantation remains unknown. We present two cases of rapidly progressive diffuse cutaneous SSc (dcSSc) treated with AHSCT following inadequate response to conventional immunosuppressive therapy. While both patients experienced significant cutaneous improvement post-AHSCT, internal organ involvement progressed in one case, ultimately resulting in a fatal outcome due to severe sepsis, whereas the second patient remained clinically stable and without immunosuppressive therapy during long-term follow-up. This report contributes to the growing body of evidence supporting AHSCT as a therapeutic option in carefully selected cases of progressive dcSSc. To our knowledge, our cases are the first successful experiences with this treatment modality in Croatia and among the Slavic populations of the Balkan Peninsula, promoting the need for earlier interventions in patients who develop a progressive disease course, particularly with skin involvement.
Ethics Approval
The study was approved by the Ethics committee of University Hospital Centre Zagreb (approval number: 8.1-23/249-2; 02/013 AG).
References
- Denton CP. Advances in pathogenesis and treatment of systemic sclerosis. Clin Med 2016; 16: 55-60. DOI: https://doi.org/10.7861/clinmedicine.16-1-55
- Denton CP, Khanna D. Systemic sclerosis. Lancet 2017; 390: 1685-99. DOI: https://doi.org/10.1016/S0140-6736(17)30933-9
- Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C, et al. Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheumatol 2017; 69: 1067-77. DOI: https://doi.org/10.1002/art.40027
- Elhai M, Meune C, Boubaya M, Avouac J, Hachulla E, Balbir-Gurman A, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76: 1897-905. DOI: https://doi.org/10.1136/annrheumdis-2017-211448
- Cen X, Feng S, Wei S, Yan L, Sun L. Systemic sclerosis and risk of cardiovascular disease: a PRISMA-compliant systemic review and meta-analysis of cohort studies. Medicine 2020; 99: e23009. DOI: https://doi.org/10.1097/MD.0000000000023009
- Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, Čolić J, Santiago T, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 2025; 84: 29-40. DOI: https://doi.org/10.1136/ard-2024-226430
- Higashitani K, Takase-Minegishi K, Yoshimi R, Kirino Y, Hamada N, Nagai H, et al. Benefits and risks of haematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis. Mod Rheumatol 2023; 33: 330-7. DOI: https://doi.org/10.1093/mr/roac026
- Schmalzing M, Henes J, Van Laar JM, Sullivan KM. Editorial: Stem cell transplantation in autoimmune diseases (AID). Front Immunol. 2023;14:1150664. DOI: https://doi.org/10.3389/fimmu.2023.1150664
- Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15. DOI: https://doi.org/10.1136/ard.2009.114264
- Jones XM, Bottini N, Boin F, Marbán E. Cardiac involvement in systemic sclerosis: A critical review of knowledge gaps and opportunities. J Scleroderma Relat Disord 2025: 23971983241313096. DOI: https://doi.org/10.1177/23971983241313096
- Giucă A, Gegenava T, Mihai CM, Jurcuţ C, Săftoiu A, Gȋrniţă DM, et al. Sclerodermic cardiomyopathy-a state-of-the-art review. Diagnostics 2022; 12: 669. DOI: https://doi.org/10.3390/diagnostics12030669
- Fairley JL, O’Rourke R, Puranik R, Nikpour M. Cardiac magnetic resonance imaging in systemic sclerosis: Heart involvement in high-resolution. Rheumatol Immunol Res 2024; 5: 83-92. DOI: https://doi.org/10.1515/rir-2024-0011
- Del Papa N, Onida F, Zaccara E, Saporiti G, Maglione W, Tagliaferri E, et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant 2017; 52: 53-8. DOI: https://doi.org/10.1038/bmt.2016.211
- Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 2018; 378: 35-47. DOI: https://doi.org/10.1056/NEJMoa1703327
- Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airò P, et al. Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology 2020; 59: 1684-94. DOI: https://doi.org/10.1093/rheumatology/kez486
- Hemu M, Zimmerman A, Kalra D, Okwuosa T. Pretransplant cardiac evaluation using novel technology. J Clin Med 2019; 8: 690. DOI: https://doi.org/10.3390/jcm8050690
- Binks M. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-84. DOI: https://doi.org/10.1136/ard.60.6.577
- Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498-506. DOI: https://doi.org/10.1016/S0140-6736(11)60982-3
- Van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490-8. DOI: https://doi.org/10.1001/jama.2014.6368
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2025 the Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.